Precision Oncology News
@preconcnews.bsky.social
This feed shares top stories covering the application of genomic sequencing and other biomarker-driven approaches to guide cancer treatment. Read the latest news at https://www.precisionmedicineonline.com/cancer
Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.
Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms
www.precisionmedicineonline.com
February 4, 2026 at 4:40 AM
Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.
The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.
Merck Pushes Back on Slowdown Assumptions, Defends Oncology Pipeline Potential
www.precisionmedicineonline.com
February 3, 2026 at 7:35 PM
The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.
CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.
CIRM Earmarks $100M For Rare Disease Platform Therapies in New RAPID Program
www.precisionmedicineonline.com
February 3, 2026 at 5:32 PM
CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.
Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.
Eli Lilly Expanding Hearing Loss Gene Therapy Push With $1B Seamless Therapeutics Pact
www.precisionmedicineonline.com
February 3, 2026 at 3:38 PM
Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.
Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.
Advocacy Groups Challenge NICE Decision to Limit Tecartus Access in England, Wales
www.precisionmedicineonline.com
February 2, 2026 at 7:46 PM
Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.
The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.
Caring Cross Plans Sickle Cell Gene Therapy Trials in India, Brazil While Amassing Data for FDA
www.precisionmedicineonline.com
February 1, 2026 at 4:14 PM
The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection
www.precisionmedicineonline.com
January 31, 2026 at 4:20 PM
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection
www.precisionmedicineonline.com
January 31, 2026 at 3:01 AM
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.
Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'
www.precisionmedicineonline.com
January 31, 2026 at 1:32 AM
Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Four-Biomarker Blood Test Could Improve Early Pancreatic Cancer Detection
www.precisionmedicineonline.com
January 30, 2026 at 3:33 PM
The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Four-Gene Blood Biomarker Test Could Improve Early Pancreatic Cancer Detection
www.precisionmedicineonline.com
January 30, 2026 at 1:57 AM
The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.
Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.
Roche Anticipating Giredestrant Approval in 2026, Touts 'Discipline' and 'Stability'
www.precisionmedicineonline.com
January 30, 2026 at 12:44 AM
Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.
UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.
Huntington's Groups Urge FDA to Review UniQure's Gene Therapy
www.precisionmedicineonline.com
January 29, 2026 at 8:24 PM
UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.
Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.
Genetic Testing Driving Increase in Medicare Lab Spending, According to HHS OIG Report
www.precisionmedicineonline.com
January 29, 2026 at 5:16 PM
Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.
After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.
Genetic Testing Challenges in Precision Medicine: Inadequate Relay of Test Limits Delays Diagnosis
www.precisionmedicineonline.com
January 29, 2026 at 3:48 AM
After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.
While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.
Legal Ruling on FDA Authority Over LDTs Raises Questions for Advanced Dx, CDx Developers
www.precisionmedicineonline.com
January 28, 2026 at 4:55 PM
While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.
After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.
Genetic Testing Challenges in Precision Medicine: Inadequate Relay of Test Limits Delays Diagnosis
www.precisionmedicineonline.com
January 28, 2026 at 2:41 AM
After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.
The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in hypercholesterolemia.
CRISPR Biotech Scribe Therapeutics Advancing First Medicine Into Clinic This Year
www.precisionmedicineonline.com
January 27, 2026 at 9:54 PM
The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in hypercholesterolemia.
While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.
Legal Ruling on FDA Authority Over LDTs Raises Questions for Advanced Dx, CDx Developers
www.precisionmedicineonline.com
January 27, 2026 at 3:40 PM
While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.
At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.
Moderna Assures Vaccine De-prioritization in US Doesn't Apply to Cancer
www.precisionmedicineonline.com
January 24, 2026 at 1:38 AM
At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.
Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, researchers are calling for prospective validation.
Can the Time of Day Patients Receive CAR-T Therapy Influence How Well They Do?
www.precisionmedicineonline.com
January 23, 2026 at 6:44 PM
Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, researchers are calling for prospective validation.
Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and showed its potential as a non-invasive companion diagnostic.
Circulating Tumor Cell Assay Finds Best Responders to Amgen's Small Cell Lung Cancer Drug
www.precisionmedicineonline.com
January 22, 2026 at 5:44 PM
Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and showed its potential as a non-invasive companion diagnostic.
Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.
Mira Precision Health Enters US DPYD Testing Market With Expanded Assay for Chemo Risks
www.precisionmedicineonline.com
January 22, 2026 at 3:20 AM
Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.
If the provision passes as part of the bill, it would address a major priority of many firms in the MCED business.
Pathway to Medicare Coverage for MCED Tests Included in Federal Spending Package
www.precisionmedicineonline.com
January 22, 2026 at 1:42 AM
If the provision passes as part of the bill, it would address a major priority of many firms in the MCED business.
The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.
J&J Expects Multiple Myeloma Programs to Benefit From FDA MRD Guidance
www.precisionmedicineonline.com
January 21, 2026 at 9:20 PM
The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.